Cardi

Cardi asked about the improvement in ARC-20 monotherapy ORR from the 30s to mid-40s, specifically how much was due to deepening responses and when these responses started to deepen. Cardi also inquired about the clinical and R&D expense impact if STAR-121 is discontinued after its futility analysis.

Answer

CEO Terry Rosen confirmed the ORR improvement was due to deepening responses, occurring at various time points, even past a year, highlighting the durability. Terry noted minimal operational impact from STAR-121 discontinuation as it's mostly enrolled. CFO Bob Goeltz added that most R&D expenses for late-stage trials are incurred during enrollment and early treatment, decreasing significantly later.